G1 Therapeutics (GTHX) News Today $7.11 +0.01 (+0.14%) (As of 10:46 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 Time Period August 20 at 10:28 PM | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, OBDC, PETQ on Behalf of ShareholdersAugust 16, 2024 | marketbeat.comVanguard Group Inc. Raises Stock Holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX)Vanguard Group Inc. grew its stake in G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) by 5.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,081,573 shares of the company's stockAugust 13, 2024 | americanbankingnews.comWedbush Equities Analysts Boost Earnings Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX)August 12, 2024 | marketbeat.comQ3 2024 EPS Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) Raised by AnalystG1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Stock analysts at Wedbush raised their Q3 2024 earnings per share estimates for G1 Therapeutics in a research report issued to clients and investors on Thursday, August 8th. Wedbush analyst D. Nierengarten now anticipates that the company will pAugust 9, 2024 | globenewswire.comGTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.August 9, 2024 | markets.businessinsider.comHold Rating Affirmed Amid G1 Therapeutics’ Acquisition by PharmacosmosAugust 9, 2024 | bizjournals.comIn $400M deal for Triangle firm, familiar name is largest shareholderAugust 9, 2024 | msn.comNeedham Downgrades G1 Therapeutics (GTHX)August 9, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of ShareholdersAugust 9, 2024 | marketbeat.comG1 Therapeutics, Inc. to Post Q3 2025 Earnings of ($0.04) Per Share, Wedbush Forecasts (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Equities researchers at Wedbush dropped their Q3 2025 earnings per share (EPS) estimates for G1 Therapeutics in a research report issued to clients and investors on Wednesday, August 7th. Wedbush analyst D. Nierengarten now forecasts that the coAugust 9, 2024 | marketbeat.comHC Wainwright Lowers G1 Therapeutics (NASDAQ:GTHX) to HoldHC Wainwright downgraded shares of G1 Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday.August 8, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Forecasted to Earn FY2027 Earnings of $0.16 Per ShareG1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Research analysts at Wedbush increased their FY2027 EPS estimates for G1 Therapeutics in a research note issued to investors on Wednesday, August 7th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $0.16 per share for tAugust 8, 2024 | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Downgraded by WedbushWedbush lowered shares of G1 Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday.August 8, 2024 | globenewswire.comG1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational HighlightsAugust 7, 2024 | marketwatch.comG1 Therapeutics Shares Hit 52-Week High on Deal to Be AcquiredAugust 7, 2024 | stockhouse.comGTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to ShareholdersAugust 7, 2024 | bizjournals.comRTP company taken private in $405 million dealAugust 7, 2024 | markets.businessinsider.comG1 Therapeutics To Be Acquired By Pharmacosmos For $7.15/shr In CashAugust 7, 2024 | msn.comG1 Therapeutics Q2 2024 Earnings PreviewAugust 7, 2024 | bizjournals.comRTP drugmaker G1 Therapeutics taken private in $405 million dealAugust 7, 2024 | msn.comG1 Therapeutics surges on merger deal with PharmacosmosAugust 7, 2024 | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of G1 Therapeutics in a research note on Wednesday.August 7, 2024 | marketbeat.comG1 Therapeutics Target of Unusually High Options Trading (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 4,302 call options on the company. This is an increase of approximately 135% compared to the average daily volume of 1,832 call options.August 7, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public ShareholdersAugust 7, 2024 | investorplace.comWhy Is G1 Therapeutics (GTHX) Stock Up 66% Today?August 7, 2024 | globenewswire.comPharmacosmos Group to Acquire G1 TherapeuticsAugust 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2024 | marketbeat.comG1 Therapeutics (GTHX) to Release Quarterly Earnings on ThursdayG1 Therapeutics (NASDAQ:GTHX) will be releasing earnings before the market opens on Thursday, August 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=613217)July 28, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest UpdateG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 7,030,000 shares, an increase of 23.6% from the June 30th total of 5,690,000 shares. Based on an average trading volume of 1,530,000 shares, the short-interest ratio is presently 4.6 days.July 26, 2024 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are retail investors with 56% stake, while 28% is held by institutionsJuly 25, 2024 | globenewswire.comG1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024July 25, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Bought by Acadian Asset Management LLCAcadian Asset Management LLC increased its stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) by 643.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 433,709 shares of the company's stock after purchasJuly 15, 2024 | investorplace.comG1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025July 10, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 10, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 9, 2024 | insidertrades.comJohn E. (Jack) Jr. Bailey Sells 7,662 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) StockJuly 1, 2024 | globenewswire.comG1 Therapeutics Added to the Russell 2000® and 3000® IndexesJune 27, 2024 | marketbeat.comFY2024 Earnings Forecast for G1 Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Research analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of G1 Therapeutics in a note issued to investors on Tuesday, June 25th. HC Wainwright analyst E. White now anticipates that the company will post earnings of (June 25, 2024 | marketbeat.comNeedham & Company LLC Trims G1 Therapeutics (NASDAQ:GTHX) Target Price to $6.00Needham & Company LLC dropped their price target on shares of G1 Therapeutics from $12.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday.June 24, 2024 | marketbeat.comWedbush Reaffirms Outperform Rating for G1 Therapeutics (NASDAQ:GTHX)Wedbush reaffirmed an "outperform" rating and issued a $3.00 target price (down previously from $5.00) on shares of G1 Therapeutics in a research report on Monday.June 24, 2024 | marketbeat.comStock Traders Purchase High Volume of Put Options on G1 Therapeutics (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of unusually large options trading activity on Monday. Investors purchased 3,989 put options on the stock. This represents an increase of approximately 97% compared to the typical daily volume of 2,023 put options.June 24, 2024 | investorplace.comWhy Is G1 Therapeutics (GTHX) Stock Down 56% Today?June 24, 2024 | globenewswire.comG1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)June 13, 2024 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for G1 Therapeutics (NASDAQ:GTHX)Needham & Company LLC reissued a "buy" rating and issued a $12.00 target price on shares of G1 Therapeutics in a report on Thursday.June 5, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest Up 26.9% in MayG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 3,590,000 shares, an increase of 26.9% from the April 30th total of 2,830,000 shares. Based on an average daily volume of 1,380,000 shares, the short-interest ratio is presently 2.6 days.May 28, 2024 | markets.businessinsider.comBuy Rating Affirmed: G1 Therapeutics’ Cosela Shows Significant Survival Benefits in mTNBCMay 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for G1 Therapeutics Amid Promising Clinical OutcomesMay 28, 2024 | msn.comG1 Therapeutics slips after new breast cancer data for lead assetMay 28, 2024 | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of G1 Therapeutics in a research report on Tuesday. Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump is sounding the alarm (Ad)Europe is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared? Click here to get your complimentary retirement guide! GTHX Media Mentions By Week GTHX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GTHX News Sentiment▼0.950.44▲Average Medical News Sentiment GTHX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GTHX Articles This Week▼23▲GTHX Articles Average Week Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RIGL News Today DVAX News Today KURA News Today RCUS News Today LBPH News Today ARDX News Today OCUL News Today ANIP News Today COLL News Today EVO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GTHX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share G1 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTHX Stock Alerts